Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

This study has been terminated.
(Unexpected toxicity (2 early deaths))
Sponsor:
Information provided by (Responsible Party):
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01537861
First received: February 15, 2012
Last updated: January 21, 2015
Last verified: January 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: December 2014
  Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)